Delivery of corticosteroids through iontophoresis

ABSTRACT

Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application61/031,267, filed Feb. 25, 2008, and. U.S. Provisional Application61/047,950, filed Apr. 25, 2008, the entire contents of each of whichare incorporated herein by reference.

BACKGROUND

Corticosteroids are widely prescribed therapeutics. Systemic, topicaland injected formulations are routinely employed for a variety ofophthalmic conditions. In particular, topical applications account forthe widest use of non-invasively delivered corticosteroids for oculardisorders. This approach, however, suffers from low bioavailability and,thus, limited efficacy.

Dexamethasone, member of the glucocorticoid class of steroid hormones,acts as an anti-inflammatory and immunosuppressant. Ocular formulationsare used that allow for diffusion of dexamethasone across an ocularmembrane, however, such topical formulations suffer from slow,inadequate and uneven uptake. Because current ocular delivery methodsachieve low ocular exposures, frequent applications are required andcompliance issues are significant.

Topical dexamethasone applications involving ocular iontophoresis havenot been described. Based on commercially-available, columbic-controllediontophoresis for topical applications to the skin of a variety oftherapeutics, it is clear that even well understood pharmaceuticalsrequire customized formulations for iontophoresis. These alterationsmaximize dosing effectiveness, improve the safety and manage commercialchallenges. The known technical formulation challenges presented bydermatological applications may translate in to ocular delivery.However, ocular iontophoresis presents additional formulation needs.Thus, developing novel formulations that are ideally suited for oculariontophoretic delivery of corticosteroids is required. Such formulationsinclude many variables, including: API concentration, solute,excipients, stabilizers, buffering agents, delivery applicator,iontophoretic dose, etc. Developing corticosteroids suitable fornon-invasive local ocular delivery will significantly expand treatmentoptions for ophthalmologists.

SUMMARY

Described herein are devices and methods for enhancing the delivery ofnegatively charged compounds into and through tissues, e.g., the eye.More specifically, the methods and devices described herein utilizeiontophoresis to actively deliver a compound, e.g., dexamethasonephosphate, into a mammalian eye. The methods and devices focus ondeveloping corticosteroid formulations and use of these formulations tomaximize drag delivery, e.g., through iontophoresis, and patient safety.These novel formulations are suitable for treating a variety ofinflammatory-mediated ocular disorders, lire formulations, which includedifferent strengths of the active pharmaceutical ingredient (API), arecapable of being used with different iontophoretic doses (e.g., currentlevels and application times). These solutions can, for example: (1) beappropriately buffered to manage initial and terminal pHs, (2) bestabilized to manage shelf-life (chemical stability), and/or (3) includeother excipients that modulate osmolarity. Furthermore, the drug productsolutions are crafted to minimize the presence of competing ions. Theseunique dosage forms can address a variety of therapeutic needs. Oculariontophoresis is a novel, non-invasive, out-patient approach fordelivering substantial amounts of APIs into many ocular tissues. Thisnon-invasive approach can lead to results comparable to or better thanthose achieve with ocular injections, without the significant risk ofinfection associated with the latter.

One embodiment is directed to a method for iontophoretically deliveringa corticosteroid, corticosteroid derivative, prodrug or salt thereofinto the eye of a subject, comprising: a) administering the compound tothe eye of the subject; and b) performing ocular iontophoresis underconditions such that the pH is between about 2.5 and about 6.5, therebydelivering the compound into the eye. In a particular embodiment, thecorticosteroid is a dexamethasone compound, derivative thereof. In aparticular embodiment, the starting pH is about 5.7. In a particularembodiment, the corticosteroid is in the form of a prodrug. In aparticular embodiment, the corticosteroid is delivered by injectionprior to iontophoresis. In a particular embodiment, the method ofinjection is selected from the group consisting of: an intracameralinjection, an intracorneal injection, a subconjonctival injection, asubtenon injection, a subretinal injection, an intravitreal injectionand an injection into the anterior chamber. In a particular embodiment,the corticosteroid is administered topically prior to iontophoresis. Ina particular embodiment, the topical administration comprises providingthe corticosteroid in a form selected from the group consisting of: aliquid solution, a paste and a hydro gel. In a particular embodiment,the corticosteroid is embedded in a foam matrix. In a particularembodiment, the corticosteroid is supported in a reservoir. In aparticular embodiment, the step of ocular iontophoresis is carried outprior to, during or after the step of administering the corticosteroid.In a particular embodiment, the compound is delivered by aniontophoretic dose of about 1.7×10 mA·min to about 120 mA·min, e.g.,between about 10 mA·min and about 30 mA·min. In a particular embodiment,the iontophoretic dose is about 20 mA·min, In a particular embodiment,the compound is delivered at a current of about 4.0 mA for a period ofabout 5 minutes. In a particular embodiment, the compound is deliveredat a variable or fixed current of less than about 10 mA. In a particularembodiment, the compound is delivered for a time of less than about 10minutes.

One embodiment is directed to a kit for ionlophoretically deliveringdexamethasone into the eye of a subject, wherein the kit is to be usedfor iontophoresis between a pH range of about 2.5 to about 6.5, and anapparatus for iontophoretically delivering the compound into the eye ofa subject.

One embodiment is directed to a dexamethasone formulation suitable forocular iontophoretic delivery into the eye of a subject. In a particularembodiment, the dexamethasone is in the form of a prodrug. In aparticular embodiment, iontophoretic delivery is to be performed in a pHrange of between about 2.5 and about 6.5, In a particular embodiment,the pH is about 5.7.

One embodiment is directed to a device for delivering dexamethasone,comprising: a) a reservoir comprising at least at least one mediumcomprising a dexamethasone formulation, the reservoir extending along asurface intended to cover a portion of an eyeball; and b) an electrodeassociated with the reservoir so as to, when polarized, supply anelectric field directed through the medium and toward a surface of theeye, wherein at least a portion of the dexamethasone formulation isdelivered transdermally through the surface of the eye throughiontophoresis. In a particular embodiment, the reservoir comprises: a) afirst container for receiving the at least one medium comprising thedexamethasone formulation; b) a second container for receiving anelectrical conductive medium comprising electrical conductive elements;and c) a semi-permeable membrane positioned between the first and secondcontainers, the semi-permeable membrane being permeable to electricalconductive elements and non-permeable to the active substances.

One embodiment is directed to a method for treating a corticosteroidsensitive ophthalmic disease in a mammal, comprising administering aneffective amount of a corticosteroid by ocular iontophoresis. In aparticular embodiment, the ophthalmic disease is selected from the groupconsisting of: uveitis, dry eye, post operative inflammation and cornealgraft rejection. In a particular embodiment, the corticosteroid isdexamethasone phosphate. In a particular embodiment, administration ofdexamethasone phosphate occurs in a single dose.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic overview of the iontophoresis apparatus andprocedure.

FIG. 2 is a graph showing in vitro delivery of DEX phosphate.

FIG. 3 is a graph showing in vitro delivery of DEX phosphate usingvarying sodium citrate concentrations.

FIG. 4 is a graph showing linear dependence of DEX phosphate flux onapplied current (mean±SD, n=4).

FIG. 5 is an image showing the setup of iontophoretic dosing in NewZealand rabbit eyes with the EyeGate II device and generator.

FIG. 6 is a graph showing tear flow measurement in rabbits injected inthe lacrimal gland with either Concanavalin A or phosphate-bufferedsaline (n=8 for each group). Rabbits were given a single iontophoreticdose of either dexamethasone phosphate or phosphate-buffered saline onDay 2. Tear flow was measured with Schirmer strips and was recorded asthe distance in mm of flow in 5 minutes. (*=P<0.01).

FIG. 7 are representative slit-lamp microscope images of fluoresceinstaining on the ocular surface of rabbits on Day 8 of the study. Leftpanel: Group 1—Rabbit had Con A-induced dry eye and wasiontophoretically treated with saline on Day 2. Middle Panel: Group2—Rabbit had Con A-induced dry eye and was iontophoretically treatedwith Dex-P on Day 2. Right panel: Group 3—Rabbit was injected withsaline and was iontophoretically treated with saline on Day 2.

FIG. 8 is a graph showing fluorescein staining score in rabbits after asingle iontophoretic dose of either dexamethasone phosphate solution orphosphate-buffered saline in the lacrimal gland (n=8 for each group).*=P<0.01).

FIG. 9 is a graph showing the expression of interleukin-1beta (IL-1β) inthe lacrimal glands and corneas of rabbits on Day 4 or Day 8 afterlacrimal gland injection of concanavalin A or saline and iontophoretictreatment with dexamethasone phosphate or saline on Day 2. n=4,*=P<0.01. No significant difference was noted in the cornea, indicatinga specific lacrimal gland inflammatory response.

FIG. 10 is a graph showing expression of transforming growth factorbeta-1 (TGF-β1) in the lacrimal glands and corneas of rabbits on Day 4or Day 8 after lacrimal gland injection of concanavalin A or saline andiontophoretic treatment with dexamethasone phosphate or saline on Day 2.n=4, *=P<0.01. No significant difference was noted in the cornea,indicating a specific lacrimal gland inflammatory response.

DETAILED DESCRIPTION

The process of iontophoresis involves applying a current to an ionizablesubstance, for example a drug product, to increase its mobility across asurface. Three principle forces govern the flux caused by the current.The primary force is electrochemical repulsion, which propels likecharged species through surfaces (tissues). The earliest investigationsof iontophoresis involve transdermal applications.

When an electric current passes through an aqueous solution containingelectrolytes and a charged material (for example, the activepharmaceutical ingredient or API), several events occur: (1) theelectrode generates ions, (2) the newly generated ions approach/collidewith like charged particles (typically the drug being delivered), and(3) the eleetrorepulsion between the newly generated ions force thedissolved/suspended charged particles (the API) into and/or through thesurface adjacent (tissue) to the electrode. Continuous application ofelectrical current drives the API significantly further into the tissuesthan is achieved with simple topical administration. The degree ofiontophoresis is proportional to the applied current and the treatmenttime. Corticosteroids can be delivered at fixed or variable currentsettings ranging from, for example, about 1 mA to about 10 mA. Theoverall iontophoretic dose is a function of current and time, Theiontophoretic dose, for example, can be applied over a period of lessthan about 10 minutes, less than about 15 minutes, less than about 20minutes, or about 5 minutes.

Iontophoresis occurs in water-based preparations, where ions can bereadily generated by electrodes. Two types of electrodes can be used toproduce ions: (1) inert electrodes and (2) active electrodes. Each typeof electrode requires aqueous media containing electrolytes.Iontophoresis with an inert electrode is governed by the extent of waterhydrolysis that an applied current can produce. The electrolysisreaction yields either hydroxide (cathodic) or hydronium (anodic) ions.Some formulations contain buffers, which can mitigate pH shifts causedby these ions. The presence of certain buffers introduces like chargedions that can compete with the drug product for ions generatedelectrolytically, which can decrease delivery of the drug product. Theelectrical polarity of the drug delivery electrode is dependent on thechemical nature of the drug product, specifically itspK_(a)(s)/isoelectric point and the initial dosing solution pH. It isprimarily the electrochemical repulsion between the ions generated viaelectrolysis and the drug product's charge that drives the drug productinto tissues. Thus, iontophoresis offers a significant advantage overtopical drug application, in that it increases drug absorption. The rateof drug delivery may be adjusted by varying the applied current, asdetermined by one of skill in the art.

Ocular iontophoresis has been reported in the literature, but thefundamental understanding of this approach for drug delivery, especiallyat the typically much higher currents used, is not at the same level asthat for transdermal electrotransport. The present invention, therefore,is directed to unexpected discoveries about the formulations andconditions for using particular DEX phosphate formulations for oculariontophoresis. In particular, electrical properties of the sclera(charge, perm selectivity, pi) and the basics of iontophoretic transportof model anionic species (e.g., buffered DEX phosphate) are described.

DEFINITIONS

As used herein, the term “subject” refers to an animal, in particular, amammal, e.g., a human.

As used herein, the term “efficacy” refers to the degree to which adesired effect is obtained. Specifically, the term refers to the degreeto which dexamethasone or a prodrug thereof is effective in treatinginflammation. The term “efficacy” as used in the context of the presentinvention, also refers to relief or reduction of one or more symptoms orclinical events associated with inflammation.

As used herein, “anterior uveitis” refers to an intraocular inflammationof the anterior portion of the uvea (i.e., the iris and ciliary body).“Iritis” refers to an inflammation, of the iris only, while“iridocyclitis” involves both the iris and the ciliary body. The terms“anterior uveitis”, “iritis”, and “iridocyclitis” are often usedsynonymously. Anterior uveitis is termed “acute” when the inflammationlasts less than 12. weeks or “chronic” when it lasts longer. Chronicanterior uveitis is characterized by a duration of greater than threemonths and the recurrence of the disease with multiple episodes.Recurrence indicates the return of intraocular inflammation after aperiod of quiescence.

As used herein, “DEX” generally refers to dexamethasone compounds,derivatives and salts thereof, e.g., dexamethasone phosphate,dexamethasone sodium phosphate. As used herein, the term “derivative”can refer to a chemical modification, for example, of a corticosteroid.

As used herein, “glucocorticoids” refers to corticosteroids, oftenuseful in treating various inflammation disorders. Glucocorticoids orcorticosteroids, like dexamethasone, suppress inflammation byinhibiting, for example, edema, fibrin deposition, capillary deposition,and phagocytic migration of the inflammatory response. As in othertissues, corticosteroids do not appear to have specific effects inocular tissues but exert a broad spectrum of anti-inflammatory activity.The effects of corticosteroids in ocular tissues include: 1) reductionof the cellular immune response, 2) reduction of inflammatory vascularpermeability, 3) stabilization of the blood-aqueous barrier, 4)limitation of fibrinoid exudation, 4) inhibition of fibroblasttransdifferentiation, 5) inhibition of epithelial proliferation, 6)inhibition of inflammatory corneal neovascularization, 7) retardation ofwound healing, 8) elevation of intraocular pressure, and 9) induction ofcataract. Corticosteroids also inhibit leukocyte movement to theinflamed site and may reduce the ability of leukocytes to remain in theinflamed areas.

Active Pharmaceutical Ingredients (APIs)

The present invention is directed to methods and formulations comprisingone or more of DEX, DEX phosphate and DEX sodium phosphate. Activesubstances, e.g., dexamethasone and formulations thereof, are preferablypresent in a concentration between approximately 0.1 mg andapproximately 100 mg per ml of medium.

The active substances are ionizable by themselves or are in a form thatfacilitates their ionization. Thus, it is possible to bond activesubstances to additives presenting terminating ions, such as, forexample, a polymer, a dendrimer, a polymer nanoparticle or amicrosphere, or a liposome (the active substance is then contained inthe aqueous core and not in the wall of the liposome). Various otherexamples of techniques for improving active substances ionization areknown in the art (Bourlais, C. et al. Prog. Retin Eye Res., 17:33-58,1998; Ding, S., Pharm. Sci. Tech. Today, 1:328-335 1998; Lallemand, F.el al, Eur. J. Pharm. Biopharm., 56:307-318, 2003).

Methods for Treating Ocular Inflammation

Corticosteroids have unparalleled anti-inflammatory effects and rapidonset of action. Corticosteroid ophthalmic solutions have been used totreat acute inflammatory conditions in the anterior eye tissues (McGhee,C. et al., Drug Saf., 25:33-55, 2002). Two clinical studies, forexample, demonstrate that topical application of a potent corticosteroidusing a short-term, intensive-dosing regimen alleviates acute dry eyesigns and symptoms in patients with moderate to severekeratoconjunctivitis sicca (KCS) who were unresponsive to artificialtear supplementation (Marsh, P and Pfiugfelder, S., Ophthalmology,106:811-816, 1999; Hong, S. et at, J. Ocul. Pharmacol. Titer., 23:78-82.2007). Patients experienced dry eye signs and symptoms relief for timeperiods that extended significantly beyond the active dosing period,suggesting that the treatment modified the underlying causativeinflammatory pathology. Topical corticosteroids remain the mainstaytreatment for corneal graft rejection episodes. The pharmacologicaleffects of steroids include blockage of the prostaglandin synthesis byinhibiting phospholipase A2 and the lipo-oxygenase pathways, decrease ofboth cellular and fibrinous exudation, inhibition of chemotaxis andphagocytosis, restoration of capillary permeability, stabilisation ofthe lysosomal membranes of polymorphonuclear cells (PMN), and inhibitionof graft vascularization.

Anterior uveitis encompasses a wide range of etiologies; the most commonform of anterior uveitis is of unknown etiology. The signs and symptomsof uveitis vary with etiology and location of inflammation. Anterioruveitis is differentiated from more common types of ocular inflammationby its presentation of pain or photophobia, circumlimbal redness andanterior chamber cells and flare. Patients with anterior uveitis mayexhibit symptoms of pain in one eye unless the anterior uveitis issecondary to a systemic disease, in which case pain or redness is notnecessarily a symptom. Common vision-threatening complications ofanterior uveitis (e.g., posterior subcapsular cataract (PSC), glaucomaand macular edema) generally occur due to its recurrent nature.

Medical management of anterior uveitis depends on severity and consistsof topical or systemic corticosteroid treatment and often withcycloplegics. When topical steroid drops are used, the frequency oftreatment can range from every 15 to 30 minutes, to every hour, or toevery other day depending on the severity of the inflammation beingtreated. The role of corticosteroids in treating anterior uveitis is todecrease inflammation by reducing, for example, the production ofexudates, stabilizing cell membranes, inhibiting the release of lysozymeby granulocytes, and suppressing the circulation of lymphocytes.Cycloplegics serve three purposes in the treatment of anterioruveitis: 1) to relieve pain by immobilizing the iris; 2) to preventadhesion of the iris to the anterior lens capsule (posterior synechia),which can lead to iris bombe and elevated intraocular pressure (TOP);and 3) to stabilize the blood-aqueous barrier and help prevent furtherprotein leakage (flare).

The steroid hormone dexamethasone[9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione]belongs to the class of glucocorticoid steroid hormones that cansuppress the inflammatory response to a variety of agents ofmechanical/surgical, chemical, and/or immunological nature. Theanti-inflammatory activity of dexamethasone administered systemically isabout six to ten times greater than that of prednisone or prednisoloneand about 30 to 40 times more potent than cortisone, Dexamethasone (DEX)has been shown to be effective in suppressing and/or blockinginflammation in the eye in human clinical studies and in rabbit models.

DEX is currently available in multiple commercial forms, which includesome prodrugs: dexamethasone base (alcohol), acetate or disodiumphosphate. DEX and its prodrugs can be administered orally, topically,by intravenous or intramuscular injection or inhaled. In ophthalmology,DEX disodium phosphate (Decadron® Merck & Co.) 0.1% solution has beenused. Although 0.1% solutions are widely used for ocular treatments, thedoses and durations of treatment vary considerably across individualpatients. DEX phosphate 0.1% solutions do not readily penetrate theintact cornea. Selection of the DEX dose for treatment of ocularinflammation is based mostly on clinical effectiveness data, withsupportive information from pharmacology and pharmacokinetic studies.

Patients with anterior uveitis are typically treated aggressively with apotent topical steroid agent during the initial stage of inflammation,and re-evaluated at frequent intervals, with a schedule of steroidtapering dictated by clinical response, as determined by one of skill inthe art, Thus, in practice, the principal means of regulating the dosageof a topically applied corticosteroid is to vary the frequency withwhich the medication is instilled. When a maximal effect is desired,topical steroids are administered hourly, or even more frequently. Invery severe cases of anterior uveitis, prednisolone acetate 1% ordexamethasone alcohol 0.1% may be required hourly around the clock,together with periocular and/or oral corticosteroids as adjunctivetherapy. Compliance with these regimens is often a consideration whentreatment effectiveness is being evaluated. Most treatment failures withtopical steroids are believed to be due to poor patient compliance,inadequate dosing, or abrupt or rapid tapering schedules.

In addition to uveitis, other conditions suitable for treatment byiontophoresing dexamethasone into the eye include, for example, dry eye,diabetic macular edema, age-related macular degeneration, and otherinflammatory eye conditions.

Ocular Iontophoresis Apparatus

Devices for delivering, for example, dexamethasone and suitableformulations thereof, have been described (U.S. Pat. No. 6,154,671; U.S.Pub. App. No. 2006/0142706; U.S. Pub. App. No. 2005/0245856; WO2006/072887; and U.S. Pub. App. No. 2007/0123814; the contents of eachof which are herein incorporated by reference in their entireties).

In a preferred embodiment, an iontophoretic device, with a topicalapplicator, is used to perform ocular iontophoresis. An example of sucha device is described below, however, one of skill in the art wouldappreciate that other devices suitable for ocular iontophoresis areuseful for using the formulations and methods of the present invention.

The iontophoresis applicator is annular in shape, and designed to fitover the sclera of the eye, to allow direct delivery of drug to the eye.The inner diameter of the applicator is the same diameter as the averagecornea to help facilitate the centering of the device on the eye. Theactive contact surface between the eye and the applicator consists ofsoft polyurethane hydrophilic foam; this foam serves as the reservoirfor the dexamethasone phosphate solution to be delivered duringtreatment. The electrode is inert and annular in shape to match theshape and size of the foam.

The foam reservoir can be made of hydrophilic foam that facilitates thereservoir filling process and helps eliminate air bubbles in the system.The distal part of the applicator and the foam reservoir of theapplicator function as the interface between the eye and the device. Thedimensions of these components are specifically designed to fit over thesclera, 1 mm from the limbus. The inside diameter of the applicatorserves as a viewing port to aid in placement and concentration of theapplicator.

The dimensioning and shape of the reservoir is such that the moleculesto be delivered are distributed in a homogeneous manner and on the largeocular area so as to minimize their action per area unit, and thus topreserve the superficial ocular tissue from too much stress, and also todeliver the produce precisely in targeted intraocular tissues withavoiding systemic absorption. A larger surface area allows a lowerelectric field resident time on the eyeball and limits the currentdensity on it.

The application, surface of the reservoir can be chosen for covering atarget area. It is thus not only the surface area, but also the shape ofthe reservoir that can be adapted for reaching the purpose of maximizinga homogeneous distribution of active substances. The reservoir of thedevice, for example, can be adapted to administer the active substancesvia at least a part of the cornea alone, or at least a part of thesclera and at least a part of the cornea, or at least a part of thesclera alone. In some embodiments, the application surface of thereservoir is annular and capable of extending around the optical axis ofthe eyeball.

The medium housed in the reservoir extends from a surface of theeyeball. The medium can include, for example, a natural or synthetic gelmember, a natural or synthetic foam that is geometrically andcompositionally compatible for ocular applications for receiving theactive substances in solution, or a single solution.Electrically-conductive media, such as, for example, water or hydrogel,can also be placed in the reservoir to guide and conduct the electricfield through the reservoir to the surface of the eyeball. The mediumcan also contain supplemental agents, such as, for example,electrolytes, stability additives, medicament preserving additives, pHregulating buffers, PEGylating agents and any other agent that, whenassociated, increase the half-life and/or bioavailability.

The applicator electrode can be made of. for example, a flat film with asilver coating on one surface and a conductive carbon coating on theother surface. The silver coated surface of the electrode is in contactwith the source connector pin and helps disperse the current evenlyaround the electrode, The conductive carbon is in contact with the drugproduct in the foam reservoir and serves to transfer the current to thedrug product; the carbon surface is inert and does not react with thedrug product. The electrode is, for example, about 6 mm away from thesurface of the eye to minimize any potential thermal effects from theapplicator electrode.

A passive or return electrode can be placed on a portion of the body (to“loop” current through the body), for example on an ear, the forehead ora cheek. As with the active electrode, the passive electrode can includean anode or a cathode depending upon whether the active substances arecationic or anionic. The return electrode can be very similar to, forexample, a standard TENS type electrode. It consists of multiple layersof conductive materials that are designed to allow the current to passout from the patient and back to the constant current generator. Theelectrode is flat, rectangular in shape and sized to fit on theforehead. A commercially-available conductive gel adhesive secures theelectrode to the patient.

The active, or applicator electrode, can be advantageously arranged, inoperation, to present current density of about 10 mA/cm² or less, and tobe polarized for about ten minutes or less. In some embodiments, thedevice includes a protective layer optionally formed on a surface of theactive electrode so as to protect it or to protect the inactivesubstances from metallic contaminants, as described in FR 04/04673, thecontents of which are herein incorporated by reference in its entirety.The device can be advantageously arranged in such a manner that thedistance between the active electrode and the ocular surface is chosento prevent any damage of the ocular tissue due to the electric field. Adistance from the ocular surface to the active electrode can be chosen,for example, to be at least about 4 mm.

The transfer system can be comprised of a syringe and spike, serving totransfer the drug product from a standard vial to the foam reservoir ofthe applicator. The spike, which can be fabricated from plastic, has asharp end that is used to perforate the top seal of the glass vialcontaining the DEX phosphate ophthalmic solution. The distal end of thetransfer system mates with the applicator to facilitate the transfer ofdrug product from the syringe to the applicator reservoir.Alternatively, the transfer system can be provided as a sterile,single-use, disposable product.

The iontophoresis generator can be a hand held battery operated devicedesigned to deliver a constant current to the applicator in thepredetermined range used for iontophoretic delivery of the drug product.The generator automatically ramps up the current at a predetermined rateto the desired current, as determined by one of skill in the art.

Iontophoresis Parameters

Several interdependent factors influence the overall efficacy and safetyof a particular topical steroid preparation in the treatment of ocularinflammatory disease. These include the ability of a topical steroid topenetrate through the cornea, sclera or blood-ocular barrier, relativeanti-inflammatory potency and duration of action, the dose and frequencyof administration and the adverse event profile. Given the medicalimperative to intervene early and aggressively in eyes with, forexample, anterior uveitis, and the high frequency of administrationrequired to achieve adequate therapeutic levels of steroid in theanterior chamber, alternative methods of steroid delivery into the eyeare of clinical interest.

Described herein are pertinent solution parameters that produce a DEXsodium phosphate formulation effective for delivery by oculariontophoresis. Both the upper and lower effectiveness limits of eachparameter are described, and one of skill in the art would know how toadjust these parameters to produce, for example, a controlled rate ofdrug delivery. The parameters considered are as follows:

-   1. pH This is measured by a calibrated pH meter. Various pH ranges    are obtained by pH adjustment with acid or base using various    buffering systems including, for example, phosphate buffers.-   2. Conductivity This is measured by a calibrated pH/conductivity    meter. Various conductivity ranges are obtained by altering the salt    (e.g., NaCl, KCl, etc.) concentration.-   3. Osmolarity. This is measured by a calibrated osmometer. Various    osmolarity ranges are obtained by addition of, for example,    mannitol.-   4. Ionic Strength Various ionic strengths are obtained by the    addition of various ionic compounds (e.g. NaCl, KCl, CaCl₂, MgCl₂,    etc.). Ionic strength is determined by using the following    calculation:

I=½Σc _(i) z _(i) ²

where I is ionic strength. C_(i) is the concentration of the i^(th)molecule, and z_(i), is the charge of the i^(th) molecule.

-   5. Viscosity This is measured by a calibrated viscometer. Various    viscosities are obtained by the addition of, for example, various    polyethylene glycol species (PEG's).

Other parameters that are considered in optimizing delivery of DEXinclude, for example, use of inert versus active electrodes, choice ofbuffer system, choice of excipient (possibly required for adjustingosmolarity), compound charge (e.g., pK_(a) and pI), compound solubility,API concentration, compound stability, choice of drug stabilizer,co-solvents and emulsions.

The applicator used to deliver the drug formulation utilizes anelectrode (inert or active) that stimulates the electrolysis of water toproduce ions (hydroxide or hydronium), which are required to delivercharged molecules. An anion at physiological pH, cathodic delivery(generating hydroxide ions), therefore, is required to deliver DEXphosphate. This process generates hydroxide ions that promote movementof the anionic DEX phosphate into the ocular tissues, and concurrentlyraises the pH of the drug solution. The drug product solution offerssufficient buffering capacity to accommodate all hydroxide ionsgenerated with dosing. The unique physicochemical properties of DEXphosphate, specifically the two pKa's of DEX phosphate, allow theproduction of a highly water soluble formulation with significantbuffering capacity.

An aqueous formulation of DEX would not be suitable for oculariontophoresis because DEX lacks a charged group and has very limitedaqueous solubility (0.1 mg/mL). These two shortcomings are overcome byutilizing the prodrug of dexamethasone, e.g., dexamethasone phosphate,which offers an additional advantage, internal buffering capacity. Thefinished drag product intended for iontophoretic delivery in patientswith anterior uveitis is an aqueous solution of DEX phosphate (at aconcentration of about, for example, 40 mg/mL, between about 25 and 50mg/mL; and between about 10 and 100 mg/mL) produced by methods known inthe art (e.g., by suspending the API in water for injection and thenadjusting the pH of the solution to 5.7 with sodium hydroxide). As thesolution becomes less acidic, DEX phosphate dissolves, resulting in aclear solution. In one embodiment, the finished drug product can befilter sterilized and aseptically filled into USP Type 1 glass vials.The vials can be closed with, for example, bromobutyl rubber stoppersand an aluminum overseal. The vials of finished drug product can bestored at about 2-8° C., protected from light. The product can be warmedto room temperature prior to administration.

EXEMPLIFICATION Example 1 Conditions for Ocular Iontophoresis of DEX

In vitro testing was performed at ±3 mA using a 10 mg/mL solution in 100mM sodium citrate at pH ˜5.66. Approximately 1% transferred to receptorusing cathodic delivery.

In vitro testing was performed using four different concentrations ofsodium citrate buffer to examine the effect of reducing the number ofcompeting ions on transport efficiency of DEX, Decreasing the amount ofsodium citrate increased DEX flux (see FIGS. 1 and 2). Other conditionsare varied including, for example, eliminating the pH change from thelower concentrations of sodium citrate solutions and using variousnon-charged excipients to modulate the donor solution osmolarity.

Example 2 DEX Electrotransport Across Rabbit Sclera with an InertElectrode

Described herein is a study of ocular iontophoresis: specifically, acharacterization of the barrier's permselectivity and to establishstructure-transport relationships. The electrotransport of model anioniccompounds (DEX phosphate) has been examined across rabbit sclera. DEXphosphate, a widely used ophthalmic drug, was chosen as modelnegatively-charged agent. It is a further goal to examine whether drugflux across the sclera can be optimized using the same strategies thathave proven successful for skin and, in particular, to confirm thatlinear “flux-current” relationships also apply at the higher currentdensities used in ocular delivery.

Methods

All transscleral iontophoresis studies were performed in side-by-sidediffusion cells (transport area=0.2 cm², volume—4 mL) with excisedrabbit sclera. The tissue was freed from the conjuctiva, extraocularmuscles and retina. The sclera was clamped between the two half-cells,with the conjunctival side facing the drug solution. Pt or Ag/AgClelectrodes were used to deliver the constant current, which was providedby a power supply. Each experiment was performed in at leastquadruplicate. Appropriate passive, no-current controls were performed.

Cathodal trans-scleral iontophoresis of DEX phosphate was conducted at0.5, 1, and 2 mA for 2 hours. The donor solution was 0.4% w/v DEXphosphate in water. The receptor solution was again phosphate-bufferedsaline at pH 7.4, A limited number of experiments were also carried out,in this instance, using sheep sclera. The data from these studies wereindistinguishable from those obtained using the corresponding rabbitmembranes. Samples of the receptor phase were assayed for dexamethasoneby HPLC.

Results

Iontophoretic delivery of dexamethasone phosphate across the sclera wasfacile, and the fluxes achieved after one hour were directlyproportional to the applied current (FIG. 4).

Examples 3

Testing was performed using dexamethasone and the two prodrugs, DEXsodium phosphate and DEX phosphate. Based on comparative pharmacokineticdata, DEX phosphate was selected as a suitable prodrug for iontophoreticdelivery. Since dexamethasone is considered to be the active moiety ofthe prodrugs, this section describes the pharmacology of dexamethasone.

Published literature supports the pharmacologic effect of dexamethasone,particularly in models of ocular inflammation. A number of experimentshave been reported that characterize the pharmacologic effects ofdexamethasone, both in vitro and in vivo. Often prodrugs ofdexamethasone are used in these pharmacology studies, and it is assumedthat the conversion of these prodrugs to dexamethasone occurs relativelyrapidly and completely. These combined data support that dexamethasoneefficiently and effectively inhibits inflammation. The in vitro and invivo studies leading to these findings are described herein.

Described herein are formulations and methods for delivering DEX to asubject. The iontophoretic delivery of therapeutic agents into the eyeis of interest as a means of non-invasively achieving higher drug levelsinside the eye by promoting the movement of charged substances (drugproducts) across biological membranes by applying a low electricalcurrent forming an electrical field. The electric field causeselectrorepulsions between the newly formed ions and the drug product,which propels the drug product into ocular tissue. The iontophoreticdelivery of an aqueous dosing solution of dexamethasone phosphate, ananion at physiological pH, requires cathodic electrolysis with, forexample, an inert electrode. This process generates hydroxide ions thatpromote movement of the anionic dexamethasone phosphate into the oculartissues, while concurrently raising the pH of the drug product solution.The unique physicochemical properties of DEX phosphate, specifically thetwo pKa's (1.9 and 6.4) of dexamethasone phosphate, however, allow theproduction of a highly water soluble formulation (40 mg/mL) withsignificant buffering capacity (initial pH 5.7-5.8) to accommodatehydroxide ions generated.

The biophysical and biological mechanisms responsible for the tissuepenetration of active products are not well understood. Most transdermalmodels are based on the modified Nernst-Planck equation. According tothis equation, total flux is the sum of active and passive transportmechanisms: passive diffusion, electrorepulsion, and electroosmosisflux, which are summarized in the Nernst-Planck equation below:

Flux_(total)=Flux_(passive)+Flux_(electric)+Flux_(osmotic)

FLUX_(TOTAL) =−D/(DC/DX)+(D·Z·V·F·C ₁)/(K·T)±C·U

where:D=Diffusion coefficient (characteristic of the biological membrane)dc/dx=Concentration gradientz=valenceV=Electrical fieldF=Faraday's constantK=Boltzmann's constant

T=Temperature

d=Ionized drug concentrationC=Drug concentrationu=convective flow of water

In Vitro Testing

In vitro experiments were conducted to evaluate drug product stabilityunder iontophoresis. These experiments employed Ussing chambers, using awide range of iontophoretic doses (e.g., up to 120 mA·min). Compoundconcentrations were measured using HPLC analysis coupled to a UVdetector, and standard curves were generated by testing solutions atvarious concentrations.

The donor and receiving chambers are connected by a ball and socketjoint with freshly harvested rabbit scleral tissue compressed into thejoint (using the cell clamp and tension knob). A 40 mg/mL aqueous DEXphosphate solution (pH adjusted to 5.7 with 1.0 N aqueous sodiumhydroxide) was placed in the donor chamber. The receiving chamber wasfilled with 0.9% saline. After standing at room temperature for up to120 minutes, samples were removed from the donor and accepting chambersto appraise DEX phosphate and dexamethasone concentrations. Next, inertelectrodes were placed into the donor and acceptor chambers. Theconnecting wires were configured at the generator in order to producecathodic iontophoresis. At a variety of time points, aliquots wereremoved from the donor and receiving chambers in order to quantifydexamethasone, dexamethasone phosphate, and any impurities. On average,little or no dexamethasone/dexamethasone phosphate was transferredpassively (without current) and up to 5% of the material was fluxedacross the membrane (with current). For up to 120 minutes, nosignificant impurities were detectable in the donor or receivingchambers. A linear proportional drug product concentration relationshipwas obtained.

Approximately 95% of the original DEX phosphate concentration waspresent in the donor chamber. The residual solution contained onequantifiable material (concentration >0.5%). The quantifiable materialrepresented <5% of the total area under the curve based on HPLC (UVdetection), which was dexamethasone (based on comparison to a referencestandard). No other quantifiable materials were detected.

The receptor chamber contained <5% of the total DEX phosphate that waspresent at the beginning of the study in the donor chamber. Within thereceptor chamber solution, 95% of the material was dexamethasonephosphate. The balance of the material, which represented <5% of thetotal area under the curve based on HPLC (UV detection), wasdexamethasone (based on comparison to a reference standard). No otherquantifiable materials were detected. Absorption and Ocular TissueConcentrations

The ocular tissue concentrations of DEX phosphate (the prodrug) anddexamethasone (active moiety) two hours after topical administration,subconjunctival injection and constant coulomb iontophoresis delivery ofDEX disodium phosphate were evaluated in 42 male and female Fauve deBourgogne pigmented rabbits (6/group). The seven treatments were singledoses administered to the right eye as follows;

-   Group 1: Iontophoretic device placed on right eye loaded with    Sterile Water for Injection; no current was applied;-   Group 2: Iontophoretic delivery of DEX disodium phosphate with    iontophoretic device at 2.5 mA for 5 minutes (device loaded with 0.5    mL of DEX disodium phosphate 10 mg/mL solution, Sigma)-   Group 3: Iontophoretic delivery of DEX disodium phosphate with    iontophoretic device 2.5 m A for 5 minutes (device loaded with 0.5    mL of DEX disodium phosphate 40 mg/mL solution, Sigma)-   Group 4: Iontophoretic delivery of DEX disodium phosphate with    iontophoretic device 2.5 mA for 5 minutes (device loaded with 0.5 mL    of DEX disodium phosphate 10 mg/mL solution, Abraxis)-   Group 5: Subconjunctival injection of DEX disodium phosphate (0.75    mL of DEX disodium phosphate 40 mg/mL solution, Sigma)-   Group 6: Subconjunctival injection of DEX disodium phosphate (0.75    mL of DEX disodium phosphate 10 mg/mL solution, Abraxis)-   Group 7: Topical instillation of DEX disodium phosphate (0.05 mL of    DEX disodium phosphate 10 mg/mL solution, Abraxis)

Ocular tissues and plasma collected 2 hours post dosing were analyzedfor DEX phosphate and dexamethasone concentration. Samples were analyzedby an ELISA or HPLC-MS/MS method. Iontophoresis or subconjunctivaladministration provided higher ocular tissue concentrations of DEXphosphate and dexamethasone compared to topical instillation.Subconjunctival administration resulted in very high concentrations ofDEX phosphate and dexamethasone in conjunctiva and choroid tissue. Otherocular tissues had high levels of dexamethasone and DEX phosphate.Aqueous humor concentrations correlated with iris-ciliary body tissueconcentrations two hours post dose for all dosing modalitiesinvestigated. Vitreous humor concentrations correlated with retinaconcentrations two hours post dose of all dosing modalities. Systemicexposure at two hours post dosing was very low (<100 ng/mL) foriontophoresis and topical administration of DEX disodium phosphate.Subconjunctival administration resulted in low but measurable plasmalevels (<4000 ng/mL) at two hours post dose.

The pharmacokinetics of dexamethasone and DEX phosphate afteriontophoretic administration by the iontophoretic device werecharacterized in 24 female New Zealand White rabbits. Dexamethasonephosphate (60 mg/mL) was administered iontophoretically at 3 mA for 5minutes as a single dose to both eyes or DEX phosphate 40 mg/mL wasiontophoretically delivered once daily for 3 consecutive days to botheyes. Ocular tissues and plasma were analyzed for DEX phosphate anddexamethasone concentrations by an HPLC-MS/MS method in serial samplescollected post dosing. Dose proportional increases in plasma and oculartissue concentrations and exposure measures of dexamethasone wereobserved after iontophoretic administration of the 40 mg/mL versus 60mg/mL DEX phosphate solution (Table 1).

TABLE 1 Single Dose-40 mg/mL Dex P Single Dose-60 mg/mL Dex P OcularTissue or Dex AUC_(0-6 h) Dex AUC_(0-24 h) Dex AUC_(0-6 h) DexAUC_(0-24 h) Plasma (μg · h/g or μg · h/ml) (μg · h/g or μg · h/ml) (μg· h/g or μg · h/ml) (μg · h/g or μg · h/ml) Aqueous Humor 56.5 73.8 123132 Vitreous 1.5 2.2 2.3 3.0 Choroid 24.9 35.9 49.5 66.7 Plasma 1.6 3.33.7 6.6 Single Dose-40 mg/mL Dex P Single Dose-60 mg/mL Dex P OcularTissue or Dex C_(max) Dex T_(max) Dex C_(max) Dex T_(max) Plasma ( μg·/g or μg ·/ml) (hours) (μg ·/g or μg ·/ml) (hours) Aqueous Humor 16.6 240 5 2 Vitreous 0.360 2 0.657 2 Choroid 7.43 0.25 12.5 0.25 Plasma 0.3420.25 0.997 2 Dex P = Dexamethasone Phosphate; Dex = Dexamethasone; AUG =area under the concentration-time curve over a specified time period;Tmax = time to maximum concentration; Cmax = maximum concentration

Peak dexamethasone concentrations in ocular tissues or plasma occurredrelatively rapidly, within two hours post iontophoretic dosing.Significant ocular tissue concentrations of dexamethasone occurred up tosix hours post iontophoretic dosing. In general, dexamethasone and DEXphosphate were nearly completely cleared from plasma and ocular tissueswithin 48 hours after iontophoretic administration. The choroid tissueconcentration did not decline as rapidly as that of the other oculartissues. While choroid tissue concentrations of dexamethasone and DEXphosphate were measurable at 48 hours post iontophoretic delivery of DEXphosphate, they were generally less than 10% of peak choroidconcentrations. Compared to peak concentrations of dexamethasone and DEXphosphate, plasma and ocular tissue concentrations were relatively lowat 24 hours post iontophoretic administration. At 24 hours post dosing,ocular tissues and plasma concentrations were less than 10% of peakdexamethasone or DEX phosphate concentrations in all tissues except forthe choroid. Dexamethasone and DEX phosphate concentrations in aqueoushumor correlated with concentrations in the iris-ciliary body.

The effect of pH and chemical form of DEX phosphate on dexamethasone andDEX phosphate plasma and ocular tissue concentrations after delivery byconstant coulomb iontophoresis was evaluated in 6 female New ZealandWhite rabbits. The treatments included DEX phosphate 40 mg/mL pH 5.8made from DEX phosphate free acid, DEX phosphate 40 mg/mL pH 5.8 madefrom DEX phosphate disodium salt, and DEX phosphate 40 mg/mL pH 7.0 madefrom DEX phosphate disodium salt. A single iontophoretic dose of 2.5 mAfor 5 minutes was administered. Dexamethasone concentrations in plasmaand ocular tissues were higher after iontophoretic delivery of DEXphosphate formulations prepared from DEX phosphate free acid whencompared to formulations prepared from DEX phosphate disodium salt.

TABLE 2 EVALUATION OF RABBITS/FAUVE DE STERILE WATER IN DEVICE; NO DEX-PAND DEX TOPICAL, BOURGOGNE/42 M&F CURRENT; CONCENTRATIONS AT T = 2 HOURSSUBCONJUNCTIVAL 6/GROUP SIGMA DEX DISODIUM P DETERMINED IN OCULARTISSUES INJECTION AND 10 MG/ML AND 40 MG/ML AND PLASMA CONSTANT COULOMBIONTOPHORETIC DOSE OF IONTOPHORESIS OR IONTOPHORESIS 2.5 MA FOR 5 MIN;SUBCONJ. DOSING PROVIDE DELIVERY OF ABRAXIS, DEX DISODIUM P HIGHERTISSUE DEXAMETHASONE 10 MG/ML, IONTOPHORESIS CONCENTRATIONS OF DEX-P +DISODIUM PHOSPHATE 2.5 MA FOR 5 MIN; DEX IN ALL TISSUE COMPARED IN FAUVEDE ABRAXIS DEX DISODIUM P TO TOPICAL INSTILLATION. BOURGOGNE RABBITS 10MG/ML, TOPICAL; SUBCONJUNC DOSING RESULTED ABRAXIS DEX DISODIUM P INVERY HIGH 10 MG/ML AND CONCENTRATIONS OF DEXP SIGMA DEX DISODIUM P ANDDEX IN CONJUNCTIVA 40 MG/ML AND CHOROID TISSUE. SUBCONJUNCTIVALINJECTION; AQUEOUS HUMOR SINGLE: DOSE TO RIGHT CONCENTRATIONS EYE.CORRELATE WITH IRIS-CILIARY BODY TISSUE CONCENTRATIONS 2 H POST DOSE FORALL TESTED DOSING MODALITIES. VITREOUS HUMOR CONCENTRATIONS CORRELATEWITH RETINA CONCENTRATIONS 2 H POST DOSE OF ALL TESTED DOSINGMODALITIES. SYSTEMIC EXPOSURE IS VERY LOW FOR IONTOPHORESIS AND TOPICALDOSES, SUBCONJUNC. DOSING RESULTED IN LOW BUT MEASURABLE PLASMA LEVELSAT 2 H. EVALUATION OF THE RABBITS/NEW DEX-P 40 MG/ML AND DOSEPROPORTIONAL PK CURVE OF ZEALAND WHITE/ 60 MG/ML INCREASES IN PLASMA ANDDEXAMETHASONE 24 F DOSE: 3 MA FOR 5 MIN OCULAR TISSUE PHOSPHATE SINGLEDOSE OR ONCE A CONCENTRATIONS AND ADMINISTERED BY DAY FOR 3 CONSECUTIVEEXPOSURES WERE OBSERVED CONSTANT COULOMB DAYS TO BOTH EYES. AFTERIONTOPHORETIC IONTOPHORESIS USING ADMINISTRATION OF THE 40 THE EYEGATEII MG/ML VERSUS 60 MG/ML DEVICE IN NEW DEXAMETHASONE ZEALAND RABBITSPHOSPHATE SOLUTION. DEX AND DEX-P WERE NEARLY COMPLETELY CLEARED FROMPLASMA AND OCULAR TISSUES 48 H AFTER IONTOPHORETIC ADMINISTRATION. DEXAND DEX-P CONCENTRATIONS WERE VERY LOW AFTER 24 H IN PLASMA AND OCULARTISSUES. DEX CONCENTRATIONS IN AQUEOUS HUMOR CORRELATE WITHCONCENTRATIONS IN IRIS-CILIARY BODY TISSUE. EFFECT OF PH ON RABBITS/NEWDEX-P 40 MG/MLPH 5.8 DEX CONCENTRATIONS IN DELIVERY OF ZEALAND WHITE/6FFROM DEX-P FREE ACID, PLASMA AND OCULAR TISSUES DEXAMETHASONE DEX-P 40MG/ML PH 5.8 WERE HIGHER AFTER PHOSPHATE BY FROM DEX-P DISODIUMIONTOPHORETIC DELIVERY OF CONSTANT COULOMB SALT DEX-P FORMULATIONSIONTOPHORESIS USING DEX-P 40 MG/ML PH 7.0 FROM PREPARED FROM DEX-P FREEEYEGATE II DEVICE IN DEX-P DISODIUM ACID WHEN COMPARED TO NEW ZEALANDRABBITS SALT FORMULATIONS PREPARED DOSE: 2.5 MA FOR 5 MIN FROM DEX-PDISODIUM SALT. SINGLE DOSE.

Example 4

Additional parameters for iontophoretic delivery are varied. Conditionsinclude, for example, the following:

-   -   Use of active or inert electrodes;    -   Varying osmolarity (typically from about 200-240 mOsm/L);    -   Varying the starting pH from about 2.5 to about 6.5 (typically        from about 5.7-5.8);    -   Buffer: none or use of buffering systems known in the art;    -   Choice of excipient;    -   Drug product concentration (typically about 40 mg/mL);    -   Choice of drug product stabilizer: none (in cases where a        stabilizer can be an irritant), or other stabilizer known in the        art (see below);    -   Varying co-solvents; and/or    -   Varying emulsions

Other conditions are also varied to optimize iontophoretic delivery, forexample, osmolarity can range from, for example, about 200-600 mOsm/L,from about 250-500 mOsm/L, from about 300-400 mOsm/L, or from about200-550 mOsm/L. One of skill in the art would know how to varyosmolarity to achieve optimized results.

The starting pH, typically about 2.5-7.5 can also be varied within thisrange to achieve optimized results, for example, a range of about3.0-6.5, about 3.5-6.0, about 4.0-6.0, or about 5.0-6.0 can be used.

One of skill in the art would know how to vary the buffer system used toachieve a particular pH range. Exemplary buffer systems include, forexample, lithium, sodium, potassium acetate, citrate, tartrate, etc.

One of skill in the art. would know how to vary the choice of excipient,which could be used to adjust osmolarity, for example, by usingnon-charged sugars.

One of skill in the art will recognize that conditions will vary basedon parameters such as, for example, the pK_(a) of the compound to bedelivered, the compound solubility, the concentration of the compound tobe delivered (for example, for dexamethasone, from about 1-100 mg/mL,about 5-80 mg/mL, about 10-50 mg/mL, or from about 20-50 mg/mL).

Examples of conditions include, for example, the following:

A.

Electrode: Inert

Device: EyeGate II applicator

Current pole: cathodic

Current range: 0.01-10 mA

Dose time: 1 second-10 minutes

Total iontophoretic dose (current×time in minutes): 0.01-100 mAmin

B.

Electrode: Inert

Device: EyeGate II applicator

Current pole: cathodic

Current range: 0.1-10 mA

Dose time; 30 seconds-10 minutes

Total iontophoretic dose (current×time in minutes): 0.1-100 mAmin

C.

Electrode: Inert

Device: EyeGate II applicator

Current pole: cathodic

Current range: 0.5-10 mA

Dose time: 30 seconds-5 minutes

Total iontophoretic dose (current×time in minutes): 0.5-50 mAmin

Preferred DEX formulations include, for example:

A.

Electrode: Active and inert

Osmolarity: 200-600 mOsm/L

Starting pH: 3.5-8.5

Vehicle: water for injection

Stabilizers: benzyl alcohol, benzalkonium chloride, EDTA, Citrate,Bisulfite, Metabisulfite

Concentration: 1-100 mg/mL

Storage: aerobic and anerobic

B.

Electrode: Inert

Osmolarity: 200-400 mOsm/L

Starting pH: 5.4-6.4

Vehicle: water for injection

Stabilizers: 0.1% benzyl alcohol, 0.01% benzalkonium chloride, 0.1%EDTA, 0.65%

-   -   Citrate, 0.1% Bisulfite. 0.1% Metabisulfite

Buffer: lithium, sodium, potassium acetate, citrate, tartrate, etc

Choice of excipient: non-charged sugars

Concentration: 1-60 mg/mL

Storage: aerobic and anerobic

C.

Electrode: Inert

Osmolarity: 200-300 mOsm/L

Starting pH: 5.7-6.1

Vehicle: water for injection

Concentration: 40 mg/mL

Example 5 Single-Dose Treatment with Dexamethasone Phosphate ResolvesConcanavalin A-Induced Dry Eye in Rabbits

Current treatment options for dry eye include long-term treatment withartificial tears, topical corticosteroids such as prednisolone, andpunctal plugs, which may result in immediate effects. These treatmentscan be combined with topical cyclosporine A (Restasis®), which can takeup to six months to improve symptoms. Daily, multiple doses of topicalcorticosteroids are required for effectiveness. Long-term dexamethasonetreatment, however, can have negative effects such as elevatedintraocular pressure. ‘The efficacy of a singleiontophoretically-delivered dexamethasone phosphate (Dex-P) in rabbitswith concanavalin A-induced dry eye was assessed.

Induction of Dry Eye in Rabbits

300 μg of Concanavalin A (Sigma) in 30 mL of phosphate-buffered saline(PBS) or PBS alone were injected into the lacrimal glands of white NewZealand rabbits to induce inflammation leading to dry eye symptoms,which is a well-established model of dry eye syndrome.

Iontophoretic Drug Delivery

48 hours after lacrimal gland injection, rabbits were given a single 15mA-min (−3.0 mA for 5 min) iontophoretic dose of dexamethasone phosphate(40 mg/mL) or phosphate-buffered saline using the EyeGate II device(EyeGate Pharmaceuticals, Inc) (FIG. 5). The animals were assigned tothe following treatment groups:

Group 1: Con A injection on Day 0, Treatment with Dex-P on Day 2Group 2: Con A injection on Day 0, Treatment with PBS on Day 2Group 3: PBS injection on Day 0, Treatment with PBS on Day 2Group 4: PBS injection on Day 0 with no subsequent treatment

Clinical Observations

Animals were observed daily following Con A injection for signs ofocular inflammation. Tear flow was measured using Schirmer strips m allgroups on Days 0, 1, 2, 4, 7, and 8 after Con A injection (FIG. 6).Signs of ocular surface damage were assessed on Days 0, 2, 4, and 8using fluorescein staining and slit-lamp microscopy (FIGS. 7 and 8),Staining was scored from 0 to 2 for superior, central, and inferiorcornea for a total possible score of 6.

Cytokine Assays

Animals were euthanized on Day 4 or Day 8 following Con A injection.Upon sacrifice, the cornea and lacrimal gland were removed and snapfrozen in liquid nitrogen followed by storage at −80° C. All sampleswere homogenized by hand in a ground-glass homogenizer in 0.5 mL ofPBS+10 mM BDTA. Interleukin-1-beta (IL-1β), FIG. 9, and transforminggrowth factor beta-1 (TGF-β1), FIG. 10, were measured in lacrimal glandand corneal extracts using human IL-1β or TGF-β1 ELISA kit (R&D SystemsDuoSet FLI5A development system) according to manufacturer'sinstructions. Results were normalized for total protein concentrationmeasured in the protein assay. Due to the high homology between rabbitand human IL-1β and TGF-β1, human kits are appropriate for detecting therabbit cytokine.

CONCLUSIONS

A single iontophoretic dose of dexamethasone phosphate increases tearflow in rabbits and decreases the amount of ocular surface damagecompared to control groups. Reduced IL-1β and TGF-β1 expression isobserved in the lacrimal glands of eyes treated with a singleiontophoretic dose of dexamethasone phosphate compared to salinetreatment and control groups. No significant elevation of inflammatorycytokines in the cornea is observed on Day 4 and Day 8, indicating aspecific inflammatory response of the lacrimal gland. A singleiontophoretic dose of corticosteroid is a safer and more effectivealternative than multiple, daily topical doses,

OTHER EMBODIMENTS

Other embodiments will be evident to those of skill in the art. Itshould be understood that the foregoing detailed description is providedfor clarity only and is merely exemplary. The spirit and scope of thepresent invention are not limited to the above examples, but areencompassed by the following claims. All references cited herein areincorporated by reference in their entireties.

1-28. (canceled)
 29. A method for iontophoretically deliveringdexamethasone phosphate into the eye of a subject in need of suchtreatment, comprising: a) administering a formulation of dexamethasonephosphate to the eye of the subject; wherein the formulation comprises:i) 25 mg/mL to 40 mg/mL of a dexamethasone phosphate solution; and ii)wherein the pH of the formulation has been adjusted to between 5.7 and6.1 with a buffering agent; and b) performing ocular iontophoresis tothe eye of the subject.
 30. The method of claim 29, wherein the subjectis being treated for an ophthalmic condition selected from uveitis, dryeye, post-operative inflammation, diabetic macula edema and cornealgraft rejection.
 31. The method of claim 29, wherein the subject isbeing treated for an inflammatory ophthalmic condition.
 32. The methodof claim 29, wherein the subject is being treated for uveitis.
 33. Themethod of claim 29, wherein the subject is being treated for anteriorsegment uveitis or dry eye.
 34. The method of claim 29, wherein the stepof ocular iontophoresis is carried out prior to, during or after thestep of administering the dexamethasone phosphate.
 35. The method ofclaim 29, wherein the dexamethasone phosphate is delivered by aniontophoretic dose of about 0.5 mAmin to about 50 mAmin.